Frequency Therapeutics reports trial fail and lays off over half of staff — stock capsizes
Frequency Therapeutics announced Monday morning that its lead candidate, a drug for hearing loss, failed a Phase IIb study. As a result, the Lexington, MA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.